Sagent Pharmaceuticals has launched vinorelbine injection, USP, an anti-mitotic chemotherapy drug. Sagent will begin marketing and shipping vinorelbine injection immediately.
Sagent’s vinorelbine injection is offered in 10mg per 1ml and 50mg per 5ml, latex-free and preservative-free, single-dose vials that incorporate easy-to-read product and dosage information.
Vinorelbine injection is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced non-small cell lung cancer (NSCLC).
Michael Logerfo, corporate vice president of Sagent, said: “Sagent has launched six products in the third quarter of 2009, including vinorelbine, our third oncolytic product. Our innovative business model enables us to provide our customers with a broad range of products and delivery systems with features designed to help enhance safety and convenience.
“We continue to receive positive feedback from our customers who often consider the enhanced features of our products to be important factors when making their purchasing decisions.”